Related Experiment Videos

Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein:

Beatriz Paradela-Dobarro1, Sergio Raposeiras-Roubín, Bruno K Rodiño-Janeiro

  • 1Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain.

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|May 14, 2013
PubMed

Insights

High sensitivity C-reactive protein (hsCRP) and advanced glycation end-products (AGEs) are linked in acute myocardial infarction (AMI) patients. Statin treatment appears to modulate this relationship, particularly in non-diabetic individuals.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • High sensitivity C-reactive protein (hsCRP) and advanced glycation end-products (AGEs) are implicated in inflammation and atherosclerosis.
  • Investigating the interplay between hsCRP and AGEs is crucial for understanding acute myocardial infarction (AMI) pathogenesis.

Purpose of the Study:

  • To examine the association between AGEs and hsCRP levels in patients diagnosed with AMI.
  • To explore potential modulating effects of diabetes and statin therapy on this association.

Main Methods:

  • A cross-sectional study was conducted on 156 AMI patients between 2009-2011.
  • Plasma levels of AGEs and hsCRP were measured.
  • Statistical analyses assessed the correlation between AGEs and hsCRP, stratified by diabetes status and prior statin use.

Main Results:

  • No significant difference in AGE or hsCRP levels was found between diabetic and non-diabetic AMI patients.
  • A direct association between AGE and hsCRP was observed, primarily in diabetic patients (r=0.258, p=0.018).
  • This association was absent in patients treated with statins but maintained in statin-naïve non-diabetic patients (r=0.634, p<0.001).

Conclusions:

  • This study provides the first human evidence of a feedback mechanism between C-reactive protein (CRP) and the AGE-RAGE axis.
  • Statin therapy appears to modulate the relationship between CRP and AGEs in AMI patients.
  • The findings suggest a potential therapeutic target for managing inflammation and atherosclerosis in AMI.
Abstract

Keywords:
Acute myocardial infarctionAdvanced glycation end-products (AGEs)Cardiovascular biomarkersHigh sensitivity C-reactive protein (hsCRP)Statins

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...